{"nctId":"NCT00276016","briefTitle":"The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)","startDateStruct":{"date":"2006-01"},"conditions":["Rhinitis, Allergic, Seasonal"],"count":39,"armGroups":[{"label":"Phenylephrine, Pseudoephedrine, Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: phenylephrine","Drug: pseudoephedrine","Drug: placebo"]},{"label":"Pseudoephedrine, Placebo, Phenylephrine","type":"EXPERIMENTAL","interventionNames":["Drug: phenylephrine","Drug: pseudoephedrine","Drug: placebo"]},{"label":"Placebo, Phenylephrine, Pseudoephedrine","type":"EXPERIMENTAL","interventionNames":["Drug: phenylephrine","Drug: pseudoephedrine","Drug: placebo"]},{"label":"Phenylephrine, Placebo, Pseudoephedrine","type":"EXPERIMENTAL","interventionNames":["Drug: phenylephrine","Drug: pseudoephedrine","Drug: placebo"]},{"label":"Pseudoephedrine, Phenylephrine, Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: phenylephrine","Drug: pseudoephedrine","Drug: placebo"]},{"label":"Placebo, Pseudoephedrine, Phenylephrine","type":"EXPERIMENTAL","interventionNames":["Drug: phenylephrine","Drug: pseudoephedrine","Drug: placebo"]}],"interventions":[{"name":"phenylephrine","otherNames":[]},{"name":"pseudoephedrine","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Skin test positive for the grass pollen allergen used in the chamber at Screening or within the prior 12 months.\n* A negative urine pregnancy test at Screening and at monthly intervals for female subjects of childbearing potential.\n* The following minimum scores at an evaluation time point during each of the 120-minute screening period challenge sessions:\n\n  1. Nasal Congestion Score of at least 2 (moderate);\n  2. Total Nasal Symptoms Score of at least 6;\n  3. Total Non-nasal Symptoms Score of at least 2.\n* Freedom from any clinically significant disease, other than SAR, that would interfere with the study evaluations.\n\nExclusion Criteria :\n\n* An upper or lower respiratory tract infection within 4 weeks before Screening.\n* Dependence upon nasal, oral, or ocular decongestants, nasal topical antihistamines, or nasal steroids, in the opinion of the investigator.\n* A known potential for hypersensitivity, allergy, or idiosyncratic reaction to the study drug or excipients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo","description":"To evaluate the effect of phenylephrine 12-mg immediate-release capsule on nasal congestion in subjects with seasonal allergic rhinitis (SAR) who have been exposed to pollen for 6 hours in the Vienna Challenge Chamber (VCC). The average change from the Baseline was evaluated immediately before treatment start, over the first 6 hour post-dosing.\n\nThe values for the scale are 0,1,2,3 for measure of symptoms, defined as 0-none, 1-mild, 2-moderate, 3-severe. They are subject-evaluated results.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"0.36"},{"groupId":"OG001","value":"2.20","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.44"},{"groupId":"OG001","value":"-0.18","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Pseudoephedrine and Placebo.","description":"To estimate the effect of a pseudoephedrine (PSE) 60 mg immediate release tablet on nasal congestion over a 6-hour observation period relative to placebo\n\nThe values for the nasal congestion score scale are 0,1,2,3 for measure of symptoms, defined as 0-none, 1-mild, 2-moderate, 3-severe. They are subject-evaluated results.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"0.36"},{"groupId":"OG001","value":"2.20","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.44"},{"groupId":"OG001","value":"-0.12","spread":"0.44"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":39},"commonTop":[]}}}